Cardlytics CDLX · NASDAQ
$1.80 -3.74% (-$0.07)
Summary
38 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 7.9% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 4.5% a year over 5 years. Over the last 3 years it fell by 7.9% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $100.3M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 9
- Sell 2
Today's price within the analysts' price targets
The average target of $1 is 44% below today's price. 27% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Cost per Redemption 51%
- Cost per Served Sales 31%
- Bridg Subscription Revenue 8.2%
- Bridg Total Revenue 8.2%
- Cost Other 1.6%
By region
- UNITED STATES 100%
Cost per Redemption brings in 51% of revenue. Cost Other grew fastest, by 30% a year.
Segments in detail